Tizanidine Tablet
Product Images NDC 0904-6418

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 0904-6418). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C60e85a2 4d5a 4507 B577 7ab40184df0b 00

Label for tizanidine tablets, USP 4 mg, unit dose packaging by Major Pharmaceuticals. It includes the proprietary and generic name, strength, NDC 0904-6418-61, and indicates 100 tablets in the package. The label states the product is Rx only and not interchangeable with tizanidine capsules or Zanaflex capsules. It provides storage instructions, usual dosage directions to see product insert, and warnings to keep out of children's reach and that the unit dose package is not child resistant.*

FDA Label Image

Figure-1.jpg (Figure 1)

A line graph showing mean tizanidine concentration in plasma over time (hours from dosing) for tizanidine tablets and capsules (each 2 x 4 mg) under fasted and fed conditions. The y-axis represents plasma tizanidine concentration (ng/mL), and the x-axis represents hours from dosing. Multiple curves compare different formulations and conditions.*

FDA Label Image

Figure-2.jpg (Figure 2)

Line graph titled 'Single Dose Study—Mean Change in Muscle Tone from Baseline as Measured by the Ashworth Scale ± 95% Confidence Interval' showing changes in muscle tone over 6 hours post-dose for 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis represents improvement in Ashworth score, with negative values indicating improvement, and the x-axis shows hours post-dose from 0 to 6.*

FDA Label Image

Figure-3.jpg (Figure 3)

A line chart showing the mean change in muscle tone measured by the Ashworth scale after dosing over three time points: end of titration (week 3), end of maintenance (week 7), and endpoint (last observation). The chart compares tizanidine (mean dose 28.8 mg) to placebo, with tizanidine showing a more negative mean Ashworth score, indicating greater improvement in muscle tone, including 95% confidence intervals.*

FDA Label Image

Chemical-structure (Tizanidine Imtb 01)

Chemical structure of tizanidine hydrochloride, showing its molecular arrangement including a chlorinated aromatic ring and an imidazoline moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.